Alnylam pharmaceuticals reports second quarter 2025 financial results and highlights recent period progress

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the second quarter ended june 30, 2025 and reviewed recent business highlights. “our results during the second quarter highlight alnylam's unique ability to quickly deliver and enable commercial access to innovative medicines for patients, while continuing to advance our high-value pipeline of investigational rnai therapeut.
ALNY Ratings Summary
ALNY Quant Ranking